MaaT Pharma is focused on developing microbiome-related therapies and its lead candidate is MaaT013, a treatment for acute ...

The French company has seen its microbiome therapy for patients living with treatment-induced dysbiosis hit its endpoints.

New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transplantation (allo-HSCT) recipients demonstrate that SER-155 ...

A phase 3 trial of MaaT Pharma’s graft-versus-host disease (GvHD) drug candidate has hit its primary endpoint, positioning ...

The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of ...

OCS-05 was well tolerated and improved vision and eye health in a Phase 2 trial in 33 people with optic neuritis due to MS or ...

Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.

Oculis Holding’s OCS-05 phase 2 ACUITY trial in acute optic neuritis meets primary safety endpoint and key secondary efficacy endpoints: Zug, Switzerland Tuesday, January 7, 202 ...

Getty ImagesWith around 5% of COVID-19 patients estimated to develop long COVID, it remains a global health issue.To help ...

Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical, non-clinical and ...